![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 08, 2018 5:45:53 PM
Q1 CC
"Details of the discovery and preclinical development of CMX521 will be presented next month at the International Conference on Antiviral Research. Our ongoing Phase 1 studies are designed to evaluate the pharmacokinetics, safety and tolerability of this novel nucleoside. Data from Phase 1 will allow us to choose optimize dosing regimens to take into Phase 2 efficacy studies in 2019."
"In late 2017, we initiated our first time in human study of CMX521, a nucleoside analog identified from our chemical library as a potential treatment and/or prevention for norovirus. We see this as a great commercial opportunity, as there are currently no approved therapies for the treatment of chronic norovirus infection or for use as a prevention strategy to limit the spread of an outbreak."………….
"Norovirus represents a large and costly unmet need. Each year, there are over 700 million cases resulting in 219,000 deaths. There’s also a significant economic toll, as the cost associated with norovirus is over $60 billion a year. And it’s not just a cruise ship virus, as it frequently impacts long-term care facilities and hospitals, causing ward shutdowns and infections among patients and health care providers.
Approaching the different prevention market segments will include looking at a number of important variables depending upon the setting. For example, in a norovirus outbreak, where there’s central area of control, such as in military facilities, hospitals or medical care settings, a protocol for use can be put in place to quickly disseminate an antiviral for preventing the further spread of this highly contagious virus.
We’ve already done exploratory market research with long-term care facilities, who are very interested in the CMX521 product profile, indicating that the product could have utility not only for preventing infection in patients, but also protecting staff."
Recent CMRX News
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 07/05/2024 08:05:00 PM
- Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2024 04:15:24 AM
- Chimerix Reports First Quarter 2024 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Chimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024 • GlobeNewswire Inc. • 04/24/2024 11:00:00 AM
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/16/2024 08:05:00 PM
- Chimerix Appoints Marc D. Kozin to Board of Directors • GlobeNewswire Inc. • 03/21/2024 11:00:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/29/2024 02:20:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 01:24:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:58:26 PM
- Chimerix Reports Fourth Quarter and Year End 2023 Financial Results and Provides Operational Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Chimerix to Present at TD Cowen 44th Annual Health Care Conference • GlobeNewswire Inc. • 02/27/2024 12:00:00 PM
- Chimerix to Report Fourth Quarter and Year End 2023 Financial Results and Provide an Operational Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:02:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:01:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/17/2024 01:00:36 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 10:01:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 06:28:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 06:21:16 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/14/2024 06:13:25 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 11:06:37 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:31:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:28:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 11:17:48 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM